Welcome to our dedicated page for Immunocore Holdings news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings stock.
Immunocore Holdings plc reports commercial and clinical developments for a biotechnology issuer whose Nasdaq-listed ADSs represent ordinary shares. The company uses its ImmTAX TCR bispecific immunotherapy platform across oncology, infectious disease and autoimmune programs, with KIMMTRAK (tebentafusp-tebn) approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia and the United Kingdom.
Recurring updates cover KIMMTRAK sales and long-term survival data, lifecycle-management studies in uveal and cutaneous melanoma, the PRAME-A02 candidate brenetafusp, earlier ImmTAX candidates, HIV functional-cure research, autoimmune disease pipeline activity, financial results, investor presentations and R&D governance changes.
Immunocore (Nasdaq: IMCR) provided a business update reporting its full year 2020 financial results. The company received FDA Breakthrough Therapy Designation for tebentafusp in metastatic uveal melanoma, showing a significant overall survival improvement in a Phase 3 trial (HR=0.51). As of December 31, 2020, Immunocore had $177 million in cash and raised an additional $287 million from its IPO. Revenue grew to £30.1 million, while R&D expenses decreased to £74.8 million. The company expects to submit a Biologics License Application for tebentafusp in Q3 2021.
Immunocore (Nasdaq: IMCR) announced that four abstracts on its lead program, tebentafusp, were accepted for the AACR 2021 Annual Meeting. This includes oral presentations of Phase 3 data comparing tebentafusp with investigator’s choice for first-line metastatic uveal melanoma (mUM), showcasing its efficacy. Notably, the plenary session will feature a comparison on April 10, 2021, with the presenter being Jessica C. Hassel. The second oral session on April 12, 2021, will focus on the kinetics of radiographic responses in treated mUM patients.
Immunocore (Nasdaq: IMCR) announces FDA's Breakthrough Therapy Designation for tebentafusp, targeting metastatic uveal melanoma. This designation, based on a Phase 3 trial, highlights significant patient survival benefits with a hazard ratio of 0.51 (p0.0001). Current treatment options for this aggressive cancer are limited, with potentially becoming the first new therapy in 40 years. The company is preparing to submit a Biologic License Application in Q3 2021, following the drug's previous Fast Track and orphan drug designations.